Peyrin-Biroulet L - Search Results

1

Treat to target: a proposed new paradigm for the management of Crohn's disease.

Bouguen G, Levesque BG, Feagan BG, Kavanaugh A, Peyrin-Biroulet L, Colombel JF, Hanauer SB, Sandborn WJ. Bouguen G, et al. Clin Gastroenterol Hepatol. 2015 Jun;13(6):1042-50.e2. doi: 10.1016/j.cgh.2013.09.006. Epub 2013 Sep 10. Clin Gastroenterol Hepatol. 2015. PMID: 24036054 Free article. Review.

2

Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander?

Peyrin-Biroulet L, Chamaillard M, Gonzalez F, Beclin E, Decourcelle C, Antunes L, Gay J, Neut C, Colombel JF, Desreumaux P. Peyrin-Biroulet L, et al. Gut. 2007 Apr;56(4):577-83. doi: 10.1136/gut.2005.082925. Epub 2006 Sep 6. Gut. 2007. PMID: 16956921 Free PMC article. Review. No abstract available.

3

Antimycobacterial therapy in Crohn's disease: game over?

Peyrin-Biroulet L, Neut C, Colombel JF. Peyrin-Biroulet L, et al. Gastroenterology. 2007 Jun;132(7):2594-8. doi: 10.1053/j.gastro.2007.04.027. Gastroenterology. 2007. PMID: 17570230 Review. No abstract available.

4

Association of MTRR 66A>G polymorphism with superoxide dismutase and disease activity in patients with Crohn's disease.

Peyrin-Biroulet L, Guéant-Rodriguez RM, Chen M, Bronowicki JP, Bigard MA, Guéant JL. Peyrin-Biroulet L, et al. Am J Gastroenterol. 2008 Feb;103(2):399-406. doi: 10.1111/j.1572-0241.2007.01573.x. Epub 2007 Oct 9. Am J Gastroenterol. 2008. PMID: 17925002

5

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.

Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Peyrin-Biroulet L, et al. Clin Gastroenterol Hepatol. 2008 Jun;6(6):644-53. doi: 10.1016/j.cgh.2008.03.014. Clin Gastroenterol Hepatol. 2008. PMID: 18550004

6

Crohn's disease: beyond antagonists of tumour necrosis factor.

Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, Colombel JF. Peyrin-Biroulet L, et al. Lancet. 2008 Jul 5;372(9632):67-81. doi: 10.1016/S0140-6736(08)60995-2. Lancet. 2008. PMID: 18603161 Review.

7

Crohn's disease: the hot hypothesis.

Peyrin-Biroulet L, Oussalah A, Bigard MA. Peyrin-Biroulet L, et al. Med Hypotheses. 2009 Jul;73(1):94-6. doi: 10.1016/j.mehy.2009.01.022. Epub 2009 Mar 6. Med Hypotheses. 2009. PMID: 19269107

8

Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn's disease.

Parmentier-Decrucq E, Duhamel A, Ernst O, Fermont C, Louvet A, Vernier-Massouille G, Cortot A, Colombel JF, Desreumaux P, Peyrin-Biroulet L. Parmentier-Decrucq E, et al. Inflamm Bowel Dis. 2009 Oct;15(10):1476-84. doi: 10.1002/ibd.20931. Inflamm Bowel Dis. 2009. PMID: 19291781

9

Insufficient evidence to conclude whether anti-tumor necrosis factor therapy increases the risk of lymphoma in Crohn's disease.

Peyrin-Biroulet L, Colombel JF, Sandborn WJ. Peyrin-Biroulet L, et al. Clin Gastroenterol Hepatol. 2009 Oct;7(10):1139. doi: 10.1016/j.cgh.2009.05.012. Epub 2009 May 22. Clin Gastroenterol Hepatol. 2009. PMID: 19465159 No abstract available.

10

Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis.

Peyrin-Biroulet L, Deltenre P, Ardizzone S, D'Haens G, Hanauer SB, Herfarth H, Lémann M, Colombel JF. Peyrin-Biroulet L, et al. Am J Gastroenterol. 2009 Aug;104(8):2089-96. doi: 10.1038/ajg.2009.301. Epub 2009 Jun 30. Am J Gastroenterol. 2009. PMID: 19568226 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,087 results

Search Page

Filters